177Lu-M3-12: a Novel PSMA-Targeted Radioligand Shows Higher Tumour Uptake Than 177Lu-PSMA-617 in Preclinical Study
A new preclinical study published in EJNMMI Research reports promising results for 177Lu-M3-12, an experimental PSMA-targeted radioligand designed to improve tumour targeting and potentially reduce radiation exposure to healthy tissues in prostate cancer. The treatment uses lutetium-177, the same radioactive isotope employed in 177Lu-PSMA-617 (Pluvicto), but incorporates a different molecular structure featuring a hydrophilic linker. […]
